Marinus Pharmaceuticals (NASDAQ:MRNS) Rating Lowered to Sell at StockNews.com

Marinus Pharmaceuticals (NASDAQ:MRNS) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday.

A number of other equities analysts also recently commented on MRNS. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, September 23rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research note on Tuesday. Truist Financial restated a “buy” rating and issued a $10.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, August 14th. Finally, JMP Securities reissued a “market outperform” rating and set a $10.00 target price on shares of Marinus Pharmaceuticals in a research report on Monday, September 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.83.

Marinus Pharmaceuticals Trading Up 6.4 %

Shares of Marinus Pharmaceuticals stock opened at $1.84 on Thursday. Marinus Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $11.26. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.15 and a current ratio of 2.28. The firm has a market capitalization of $101.08 million, a price-to-earnings ratio of -0.70 and a beta of 1.13. The stock has a 50 day moving average of $1.40 and a 200 day moving average of $2.67.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million for the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. During the same period in the previous year, the business posted ($0.61) EPS. As a group, research analysts predict that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several large investors have recently modified their holdings of the company. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at about $64,000. AQR Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 70.3% during the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 12,934 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Marinus Pharmaceuticals during the second quarter worth about $206,000. Finally, XTX Topco Ltd purchased a new position in shares of Marinus Pharmaceuticals during the second quarter worth about $232,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.